Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
October 31 2018 - 4:01PM
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing
company, today announced that it will host a conference call and
webcast on Wednesday, November 7, 2018, at 5:00 p.m. ET to discuss
a corporate update and results for the third quarter of 2018.
To access the call, please dial 844-348-3801
(domestic) or 213-358-0955 (international) and provide the passcode
8397886. A live webcast of the presentation will be available on
the Investors & Media section of the Editas
website.
About Editas MedicineAs a leading genome editing
company, Editas Medicine is focused on translating the power and
potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a)
genome editing systems into a robust pipeline of treatments for
people living with serious diseases around the world. Editas
Medicine aims to discover, develop, manufacture, and commercialize
transformative, durable, precision genomic medicines for a broad
class of diseases. For the latest information and scientific
presentations, please visit www.editasmedicine.com.
Contacts
Media:Cristi Barnett
(617)
401-0113cristi.barnett@editasmed.com
Investors:Mark Mullikin(617)
401-9083mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Sep 2023 to Sep 2024